<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">

Clinically Relevant DLBCL PDX Models for BTK Inhibitor Testing

The activation of Bruton's tyrosine kinase (BTK) is considered as a major oncogenic driver for various B cell-derived lymphoid cancers. Ibrutinib (a BTK inhibitor), has been approved for a range of malignancies, and has also shown encouraging efficacy in the ABC subtype of DLBCL.